Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28593603 | 0.84 | MMP2 (0.34) | MMP2ANPEP | |
| SCHEMBL19898240 | 0.84 | MMP2 (0.34) | MMP2ANPEP | |
| SCHEMBL18426092 | 0.82 | MMP2 (0.33) | MMP2ANPEP | |
| SCHEMBL4292035 | 0.82 | MMP2 (0.32) | MMP2ANPEP | |
| SCHEMBL3952269 | 0.81 | MMP2 (0.30) | MMP2ANPEP | |
| SCHEMBL3945766 | 0.81 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL3249508 | 0.81 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL26086744 | 0.81 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL3831331 | 0.79 | — | — | |
| SCHEMBL3950857 | 0.79 | MMP2 (0.32) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | MMP2 3130/4885ANPEP 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.